Frontiers in Drug Discovery | Cardiovascular and Hematologic Drugs

Original Research

Published on 10 Nov 2025

Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study

in Cardiovascular and Hematologic Drugs

Robert M. Geiger
Carlos Serna
Bhavya Bhardwaj
Tromondae K. Feaster
Ksenia Blinova

Frontiers in Drug Discovery

doi 10.3389/fddsv.2025.1679626

1,720 views
3 citations

Review

Published on 21 Nov 2023

Future treatments for the arteriopathy of ectopic calcification disorders

in Cardiovascular and Hematologic Drugs

Benjamin M. Davies
Frank Rutsch
Naren Vyavahare
Alexander Jones

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1249966

3,819 views

Original Research

Published on 08 Feb 2023

Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort

in Cardiovascular and Hematologic Drugs

Alex Pu
Gautam Ramani
Yi-Ju Chen
James A. Perry
Charles C. Hong

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1127736

5,485 views
9 citations

Review

Published on 15 Dec 2022

Novel and emerging therapies in pulmonary arterial hypertension

in Cardiovascular and Hematologic Drugs

Steven J. Cassady
Danielle Soldin
Gautam V. Ramani

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1022971

14,287 views
11 citations

Mini Review

Published on 03 Nov 2022

Oxidized phospholipids are biomarkers, drug targets, and drug leads

in Cardiovascular and Hematologic Drugs

Olga V. Oskolkova
Anna A. Birukova
Konstantin G. Birukov
Valery N. Bochkov

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1043708

5,266 views
12 citations

Original Research

Published on 18 Oct 2022

Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients

in Cardiovascular and Hematologic Drugs

Shouri Lahiri
Mitra Mastali
Jennifer E. Van Eyk
Tara C. Hitzeman
Catherine Bresee
Koen Raedschelders
Patrick D. Lyden
Roberta A. Gottlieb
James C. Fang
Robin M. Shaw

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1042737

2,360 views
2 citations

Mini Review

Published on 12 Oct 2022

Current and potential therapeutic strategies for transthyretin cardiac amyloidosis

in Cardiovascular and Hematologic Drugs

Marcus A. C. Williams
Bairavi Shankar
Joban Vaishnav
Mark J. Ranek

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1015545

7,713 views
8 citations

Specialty Grand Challenge

Published on 23 Sep 2022

The grand challenge of discovering new cardiovascular drugs

in Cardiovascular and Hematologic Drugs

Charles C. Hong

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1027401

10,118 views
17 citations

Mini Review

Published on 11 Aug 2022

Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?

in Cardiovascular and Hematologic Drugs

Chun Chou
Michael T. Chin

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.948407

5,289 views
1 citation

9 articles

articles

Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study

Future treatments for the arteriopathy of ectopic calcification disorders

Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort

Novel and emerging therapies in pulmonary arterial hypertension

Oxidized phospholipids are biomarkers, drug targets, and drug leads

Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients

Current and potential therapeutic strategies for transthyretin cardiac amyloidosis

The grand challenge of discovering new cardiovascular drugs

Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?